Neuroprotective Strategies in Alzheimer’s Disease

  • Christian Behl
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 513)


Alzheimer s disease (AD) is a deadly progressive neurodegenerative disorder. Various aspects of the biochemistry of the AD-associated amyloid ß protein (Aß) are well-described and understood. The deposition of Aß in the AD brain is one crucial hallmark of AD pathology. Consequently, the processes of the generation of Aß are the main targets for novel avenues of prevention and treatment. Besides the increasing amount of genetic information on familial forms of AD including those types caused by mutations in the AD genes APP, PSI and PS2, various genetic and non-genetic risk factors have been described. Worldwide efforts to block Aß generation or to block its deposition by immunization are of great interest but are still at a more or less experimental stage. In addition, it may be argued that the sporadic and strictly age-related forms of AD develop because the overall homeostasis of neuroprotection is disturbed rendering the nerve cells more vulnerable for exogenous insults including All Therefore, it is also wise to study neuroprotective factors and to decipher how such factors, including neurotrophins and the female sex hormone estrogen, transduce their signal leading to nerve cell protection. The identification of potential protective genes that are regulated by well known neuroprotective signals may elucidate novel targets for preventive approaches. A general and subtle neuroprotection may stabilize nerve cell survival and may leave the neurons more resistant to AD-associated pathogenetic insults.


Alzheimer Disease Senile Plaque Oxidative Stress Hypothesis Neuronal Insulin Receptor Nongenetic Risk Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alzheimer A. ber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiat Psych-Gericht Med 1907; 64:146–148.Google Scholar
  2. 2.
    Masters CL, Beyreuther K. Alzheimer s disease. BMJ 1998; 316: 446–448.PubMedCrossRefGoogle Scholar
  3. 3.
    Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer s disease. Nature 399: A23–A31.PubMedCrossRefGoogle Scholar
  4. 4.
    Haass C, Mandelkow E. Proteolysis by presenilins and the renaissance of tau. Trends Cell Biol 1999; 9:241–244.PubMedCrossRefGoogle Scholar
  5. 5.
    Whitehouse PJ, Price DL, Struble RG et al. Alzheimer s disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982; 215:1237–1239.PubMedCrossRefGoogle Scholar
  6. 6.
    Cacabelos R, Alvarez A, Lombardi A et al. Pharmacological treatment of Alzheimer disease: From psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. Drugs Today 2000; 36:415–499.PubMedGoogle Scholar
  7. 7.
    Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD et al. Complement activation by (3-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89:10016–10020.PubMedCrossRefGoogle Scholar
  8. 8.
    McGeer EG, McGeer PL. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr Pharmac Design 1999; 5: 821–836.Google Scholar
  9. 9.
    Breitner JCS. The role of antiinflammatory drugs in the prevention and treatment of Alzheimer s disease. Annu Rev Med 1996; 47:401–411.PubMedCrossRefGoogle Scholar
  10. 10.
    Eikelenboom P, Rozemuller AJM, Hoozemans JJM et al. Neuroinflammation and Alzheimer disease: Clinical and therapeutic implications. AIz Dis Ass Dis 2000; 14(Suppl 1):S54–S61.CrossRefGoogle Scholar
  11. 11.
    Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: An update. Exp Gerontol 2000; 35(9–10 SI):1363–1372.CrossRefGoogle Scholar
  12. 12.
    Beal MF. Aging, energy, and oxidative stress in neurodegenerative disorders. Ann Neurol 1995; 38:357–366.PubMedCrossRefGoogle Scholar
  13. 13.
    Behl C. Alzheimer s disease and oxidative stress: Implications for novel therapeutic approaches. Prog Neurobiol 1999; 57:301–323.PubMedCrossRefGoogle Scholar
  14. 14.
    Harman D. Aging: Phenomena and theories. Ann NY Acad Sci 1998; 854:1–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999; 56:1449–1452.PubMedCrossRefGoogle Scholar
  16. 16.
    Behl C, Davies J, Cole GM et al. Vitamin E protects nerve cells from amyloid b protein toxicity. Biochem Bioph Res Co 1992; 186:944–950.CrossRefGoogle Scholar
  17. 17.
    Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77(4):1081–1132.PubMedGoogle Scholar
  18. 18.
    Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer s disease. N Engl J Med 1997; 336:1216–1222.PubMedCrossRefGoogle Scholar
  19. 19.
    Selkoe DJ. Alzheimer s disease: Genes, proteins, and therapy. Physiol Rev 2001; 81(2):741–766.PubMedGoogle Scholar
  20. 20.
    Yankner BA. Mechanisms of neuronal degeneration in Alzheimers disease. Neuron 1996; 16:921–932.PubMedCrossRefGoogle Scholar
  21. 21.
    Behl C. Amyloid beta-protein toxicity and oxidative stress in Alzheimer’s disease. Cell Tiss Res 1997; 290:471–480.CrossRefGoogle Scholar
  22. 22.
    Mandelkow E, Mandelkow EM. Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 1995; 7(1):72–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases Trends Neurosci 1998; 21(10):428–433.Google Scholar
  24. 24.
    Chen M, Fernandez HL. Where do Alzheimer s plaques and tangles come from? Aging-induced protein degradation inefficiency. Front Biosci 2001; 6:E1–E11.PubMedCrossRefGoogle Scholar
  25. 25.
    Chapman PF, Falinska AM, Knevett SG et al. Genes, models and Alzheimer s disease. Trends Genet 2001; 17(5):254–261.PubMedCrossRefGoogle Scholar
  26. 26.
    Campion D, Dumanchin C, Hannequin D et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65(3):664–670.PubMedCrossRefGoogle Scholar
  27. 27.
    Schubert D, Behl C. The expression of amyloid beta protein precursor protects nerve cells from beta-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix. Brain Res 1993; 629:275–282.PubMedCrossRefGoogle Scholar
  28. 28.
    Mattson MP, Cheng B, Culwell AR et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10:243–254.PubMedCrossRefGoogle Scholar
  29. 29.
    Hardy J. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997; 20(4):154–159.PubMedCrossRefGoogle Scholar
  30. 30.
    Wolfe MS, Haass C. The role of presenilins in gamma-secretase activity. J Biol Chem 2001; 276(8):5413–5416.PubMedCrossRefGoogle Scholar
  31. 31.
    Skovronsky DM, Lee VMY. Beta-secretase revealed: Starting gate for race to novel therapies for Alzheimer s disease. Trends Pharmacol Sci 2000; 21(5):161–163.PubMedCrossRefGoogle Scholar
  32. 32.
    Lammich S, Kojro E, Postina R et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999; 96(7):3922–3927.PubMedCrossRefGoogle Scholar
  33. 33.
    Xu H, Gouras GK, Greenfield JP et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4:447–451.PubMedCrossRefGoogle Scholar
  34. 34.
    Manthey D, Heck S, Engert S et al. Estrogen induces a rapid secretion of amyloid 3 precursor protein via the mitogen-activated protein kinase pathway. Eur J Biochem 2001; 268:1–8.CrossRefGoogle Scholar
  35. 35.
    Yan SD, Chen X, Fu J et al. Rage and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 1996; 382(6593):685–691.PubMedCrossRefGoogle Scholar
  36. 36.
    Liu Y, Dargusch R, Schubert D. Beta amyloid toxicity does not require rage protein. Biochem Biophys Res Co 1997; 237(1):37–40.CrossRefGoogle Scholar
  37. 37.
    Behl C, Davies JB, Lesley R et al. Hydrogen peroxide mediates amyloid ß protein toxicity. Cell 1994; 77:817–827.PubMedCrossRefGoogle Scholar
  38. 38.
    Geula C, Wu CK, Saroff D et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nature Med 1998; 4(7):827–831.PubMedCrossRefGoogle Scholar
  39. 39.
    Behl C, Lezoualch F, Trapp T et a. Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinol 1997; 138(1):101–106.CrossRefGoogle Scholar
  40. 40.
    Behl C. Apoptosis and Alzheimers disease. J Neur Transm 2000; 107:1325–1344.CrossRefGoogle Scholar
  41. 41.
    Terry RD. The pathogenesis of alzheimer disease An alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996; 55(10):1023–1025.PubMedGoogle Scholar
  42. 42.
    Terry RD, Katzman R, Bick KL. Alzheimer Disease. New York: Raven Press, 1994.Google Scholar
  43. 43.
    Rebeck GW, Reiter JS, Strickland DK et al. Apolipoprotein E in sporadic Alzheimer s disease: Allelic variation and receptor interactions. Neuron 1993; 11(4):575–580.PubMedCrossRefGoogle Scholar
  44. 44.
    Richard F, Amouyel P. Genetic susceptibility factors for Alzheimer s disease. Eur J Pharmacol 2001; 412(1):1–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Simons M, Keller P, Destrooper B et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998; 95(11):6460–6464.PubMedCrossRefGoogle Scholar
  46. 46.
    : Wolozin B, Kellman W, Rousseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10):1439–1443.PubMedCrossRefGoogle Scholar
  47. 47.
    Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer s disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98(10):5856–5861.PubMedCrossRefGoogle Scholar
  48. 48.
    Kojro E, Gimpl G, Lammich S et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001; 98(10):5815–5820.PubMedCrossRefGoogle Scholar
  49. 49.
    Emilien G, Maloteaux JM, Beyreuther K et al. Alzheimer disease Mouse models pave the way for therapeutic opportunities. Arch Neurol 2000; 57(2):176–181.PubMedCrossRefGoogle Scholar
  50. 50.
    Duff K, Knight H, Refolo LM et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 2000; 7(2):87–98.PubMedCrossRefGoogle Scholar
  51. 51.
    Emilien G, Beyreuther K, Masters CL et al. Prospects for pharmacological intervention in Alzheimer disease. Arch Neurol 2000; 57(4):454–459.PubMedCrossRefGoogle Scholar
  52. 52.
    Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740):173–177.PubMedCrossRefGoogle Scholar
  53. 53.
    Janus C, Pearson J, McLaurin J et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer s disease. Nature 2000; 408(6815):979–982.PubMedCrossRefGoogle Scholar
  54. 54.
    Morgan D, Diamond DM, Gottschall PE et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer disease. Nature 2000; 408(6815):982–985.PubMedCrossRefGoogle Scholar
  55. 55.
    Lim GP, Yang F, Chu T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer s disease. J Neurosci 2000; 20(15):5709–5714.PubMedGoogle Scholar
  56. 56.
    Grundman M. Vitamin E and Alzheimer disease: The basis for additional clinical trials. Am J Clin Nutr 2000; 71(2):6305–6365.Google Scholar
  57. 57.
    Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999; 96:8867–8872.PubMedCrossRefGoogle Scholar
  58. 58.
    Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer s disease: update on a 2-year double-blind multicentre study. J Neur Transm 1998; (Suppl 54):301–310.Google Scholar
  59. 59.
    Guidetti C, Paracchini S, Lucchini S et al. Prevention of neuronal cell damage induced by oxidative stress in-vitro: Effect of different Ginkgo biloba extracts. J Pharm Pharmacol 2001; 53(3):387–392.PubMedCrossRefGoogle Scholar
  60. 60.
    Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer-disease. Arch Neurol 1998; 55(11):1409–1415.PubMedCrossRefGoogle Scholar
  61. 61.
    Wesnes KA, Ward T, McGinty A et al. The memory enhancing effects of a Ginkgo biloba/ Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacol 2000; 152(4):353–361.CrossRefGoogle Scholar
  62. 62.
    Nourhashemi F, Gillette-Guyonnet S, Andrieu S et al. Alzheimer disease: Protective factors. Am J Clin Nutr 2000; 71(2):643S–649S.PubMedGoogle Scholar
  63. 63.
    Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing v717f beta-amyloid precursor protein. Nature 1995: 373(6514):523–527.PubMedCrossRefGoogle Scholar
  64. 64.
    Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer s disease. Neurobiol Aging 1994; 15(Suppl 2):S195–S197.PubMedCrossRefGoogle Scholar
  65. 65.
    Henderson VW, Paganini-Hill A, Emanuel CK et al. Estrogen replacement therapy in older women. Arch Neurol 1994; 51:896–900.PubMedCrossRefGoogle Scholar
  66. 66.
    Tang MX, Jacobs D, Stern Y et al Effect of oestrogen during menopause on risk and age of onset of Alzheimer s disease. Lancet 1996; 348:429–432.PubMedCrossRefGoogle Scholar
  67. 67.
    Henderson VW. Oestrogens and dementia. In: Novartis Found Symp, ed. 2000; 230:254–265.PubMedCrossRefGoogle Scholar
  68. 68.
    McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999; 20:279–307.PubMedCrossRefGoogle Scholar
  69. 69.
    Behl C, Widmann M, Trapp T et al. 17–13 estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Com 1995; 216:473–482.PubMedCrossRefGoogle Scholar
  70. 70.
    Green PS, Bishop J, Simpkins JW. 17 alpha-estradiol exerts neuroprotective effects on SKN-SH cells. J Neurosci 1997; 17:511–515.PubMedGoogle Scholar
  71. 71.
    Behl C, Holsboer F. The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci 1999; 20(11):441–444.PubMedCrossRefGoogle Scholar
  72. 72.
    Behl C. Estrogen Mystery drug for the brain? The neuroprotective activities of the female sex hormone. Wien, NewYork: Springer, 2001.CrossRefGoogle Scholar
  73. 73.
    Green PS, Simpkins JW. Neuroprotective effects of estrogens: Potential mechanisms of action. Intern J Develop Neurosci 2000; 18:347–358.CrossRefGoogle Scholar
  74. 74.
    Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer s amyloid beta peptides in brain. Neurology 2000; 54:2212–2217.PubMedCrossRefGoogle Scholar
  75. 75.
    Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Rev 1996; 17:187–205Google Scholar
  76. 76.
    Lezoualc h F, Engert S, Berning B et al. Corticotropin-releasing hormone mediated neuroprotection against oxidative stress is associated with the increased release of non amyloidogenic amyloid beta precursor protein and with the suppression of nuclear factor-kappa B. Mol Endocrinol 2000; 14(1):147–159.CrossRefGoogle Scholar
  77. 77.
    Behan DP, Grigoriadis DE, Lovenberg T et al. Neurobiology of corticotropin releasing factor (CRH) receptors and CRH-binding protein: Implications for the treatment of CNS disorders. Mol Psych 1996; 1:265–277.Google Scholar
  78. 78.
    Lezoualch F, Sagara Y, Holsboer F et al. High constitutive nf-kappa-b activity mediates resistance to oxidative stress in neuronal cells. J Neurosci 1998; 18(9):3224–3232Google Scholar
  79. 79.
    Greeve I, Hermans-Borgmeyer I, Brellinger C et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer s disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 20(19):7345–7352.PubMedGoogle Scholar
  80. 80.
    Borchelt DR, Ratovitski T, Vanlare J et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19(4):939–945.PubMedCrossRefGoogle Scholar
  81. 81.
    Destrooper B, Saftig P, Craessaerts K et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998; 391(6665):387–390.CrossRefGoogle Scholar
  82. 82.
    Duff K, Eckman C, Zehr C et al. Increased amyloid-beta-42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383(6602):710–713.PubMedCrossRefGoogle Scholar
  83. 83.
    Holcomb L, Gordon MN, Mcgowan E et al. Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 1998; 4(1):97–100.PubMedCrossRefGoogle Scholar
  84. 84.
    Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, a-beta elevation, and amyloid plaques in transgenic mice. Science 1996; 274(5284):99–102.PubMedCrossRefGoogle Scholar
  85. 85.
    Sturchler-Pierrat C, Abramowski D, Duke M et al. Two amyloid precursor protein transgenic mouse models with alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997; 4(24):13287–13292.CrossRefGoogle Scholar
  86. 86.
    Zheng H, Jiang MH, Trumbauer ME et al. Beta-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995; 81(4):525–31.PubMedCrossRefGoogle Scholar
  87. 87.
    Shen J, Bronson RT, Chen DF, Xia WM, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in presenilin-1 -deficient mice. Cell 1997; 89(4):629–639.PubMedCrossRefGoogle Scholar
  88. 88.
    McGeer PL, McGeer EG, Yasojima K. Alzheimer disease and neuroinflammation. J Neural Transm Suppl 2000; 59:53–57.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Christian Behl
    • 1
  1. 1.Max Planck Institute of PsychiatryKraepelinstrasse 2-10MunichGermany

Personalised recommendations